H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $31 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
- Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)
- Nurix Therapeutics Outlines 2026 Goals and Pipeline Progress
- Nurix Therapeutics highlights key objectives, milestones
- Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley